Table 2.
Correlation between presence of at least one anti-angiogenesis-related adverse event and antitumor efficacy of apatinib
| Clinical outcomes | With adverse events (n = 150) | Without adverse events (n = 119) | Unadjusted analysis | Multi-adjusted analysisa | ||
|---|---|---|---|---|---|---|
| HR/ORb (95% CI) | P valuec | HR/OR (95% CI) | P valued | |||
| Median overall survival (IQR), days | 169 (96–255) | 103 (58–201) | 0.67 (0.51,0.88) | 0.0039 | 0.64 (0.48,0.84) | 0.001 |
| Median progression-free survival (IQR), days | 86.5 (57–150) | 62 (41–121) | 0.75 (0.58,0.98) | 0.0309 | 0.69 (0.53,0.91) | 0.007 |
| Disease control rate, n (%) | 82 (54.67) | 39 (32.77) | 2.47 (1.46,4.21) | < 0.001 | 2.67 (1.59,4.47) | < 0.001 |
| Objective response rate, n (%) | 11 (7.33) | 6 (5.04) | 1.49 (0.49.5.06) | 0.443 | 1.42 (0.50,4.01) | 0.505 |
Adverse events are defined as hypertension, proteinuria, or hand and foot syndrome in the first 4 weeks of treatment
HR hazard ratio, OR odds ratio, IQR interquartile range
aAdjusted for sex, every 10-year increase in age, number of metastatic sites and ECOG PS
bHR for overall survival and progression survival; OR for disease control rate and objective response rate
cP values calculated from log-rank test for overall survival and progression survival, and chi-square test for disease control rate and objective response rate
dP values calculated from Cox regression for overall survival and progression survival, and logistic regression for disease control rate and objective response rate